GAITHERSBURG, Md.--(BUSINESS WIRE)-- OpGen, Inc. today announced the company has entered into a scientific and technical partnership with the University of California, Davis, (UC Davis) in cooperation with the FDA supported 100K Genome Project to create high resolution microbial genetic maps. The 100K Genome Project is a collaboration that was initiated by the U.S. Food and Drug Administration (FDA), UC Davis, and Agilent Technologies to sequence the genetic code of at least 100,000 infectious organisms and accelerate the diagnosis of foodborne illnesses. UC Davis will integrate OpGens Argus Whole Genome Mapping System into its current DNA sequencing workflow for sequence assembly and validation of the genomes. Through the integration of OpGens Whole Genome Mapping technology, The 100K Genome Project will create a new gold standard for high-quality microbial reference genomes. These data will be used in the surveillance and management of international foodborne microbial outbreaks, and to establish a high-fidelity global reference database for microbial genomes. The 100K Genome Project will publish the genomes that are completed and validated using OpGens Whole Genome Maps to a database, providing access to the genomic maps for public health agencies throughout the world. The FDA is advocating rigorous quality control standards for this … Continue reading →

UMBILICAL CORD STEM CELL THERAPY We are a Ministry of Health sanctioned group of three hospitals in South China providing adult stem cell and Cancer biotherapy treatments for patients locally and from around the world. http://www.hopestemcell.com It has been proven time and time again that adult stem cells not embryonic stem cells are safe and have remarkable results. We offer highly skilled, personalized and the most cost effective care in China which is 10 years ahead of other countries in stem cell treatment and it is delivered with the maximum regard for your safety.From:Randy RobinsonViews:0 0ratingsTime:01:54More inNews Politics View post: UMBILICAL CORD STEM CELL THERAPY - Video … Continue reading →

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire - Dec 19, 2012) - TiGenix ( EURONEXT BRUSSELS : TIG ), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders. The interim results cover the first three months of the Phase IIa's six-month follow-up, and the data are still blinded. The primary endpoint of this study is safety, and the data collected so far support the good safety profile of all three doses of Cx611. Only two patients (4%) have suffered serious adverse events and only in one case (2%) it led to discontinuation of the treatment. All other side effects were mild and transient. "We … Continue reading →

BERLIN, GERMANY--(Marketwire - Dec 19, 2012) - MagForce AG / MagForce aims to raise up to EUR33.5 million . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Berlin, Germany, December 19, 2012 - MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company in the field of nanomedicine with a focus on oncology, today announced that the Company, with the approval of the Supervisory Board, has resolved a restructuring plan to safeguard MagForce's long-term existence. Under the plan, the Company's share capital is to be increased by up to EUR18.6 million by granting preemptive rights to shareholders against cash and noncash contributions. The new shares will have a notional value of EUR1.00 and will be issued for EUR1.80. As part of the capital increase, some of the company's creditors are also to be granted the right to subscribe for new shares at an issue price of EUR1.80 per share against noncash contributions to the extent that shareholders' preemptive rights are disapplied for shares counting as fractions or that preemptive rights have not been exercised following the expiration of the subscription period for all shareholders, but only up to a maximum … Continue reading →